NCT00276809 - Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions

Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL

alemtuzumab

BIOLOGICAL

filgrastim

DRUG

carmustine

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

dexamethasone

DRUG

etoposide

DRUG

fludarabine phosphate

DRUG

melphalan

PROCEDURE

autologous bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

radiation therapy

Trial Locations (12)

55101

Universitatsklinik Mainz, Mainz

76133

Staedtisches Klinikum Karlsruhe gGmbH, Karlsruhe

D-12200

Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin

D-45122

Universitaetsklinikum Essen, Essen

D-20099

Asklepios Klinik St. Georg, Hamburg

D-30625

Medizinische Hochschule Hannover, Hanover

D-69120

Universitatsklinikum Heidelberg, Heidelberg

D-24105

University Hospital Schleswig-Holstein - Kiel Campus, Kiel

D-39120

Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg, Magdeburg

D-81377

Klinikum der Universitaet Muenchen - Grosshadern Campus, Munich

D-81675

Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich

D-89081

Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm, Ulm

All Listed Sponsors

lead

German CLL Study Group

OTHER